Quest Diagnostics raises annual forecast on testing demand

Quest Diagnostics

23/07/2026 12:37

    July 23 (Reuters) - Quest Diagnostics DGX.N on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped the company beat second-quarter estimates.
Shares of the ​New Jersey-based company rose about 5% in premarket trading following the results.

Here are the details:
Demand for the company's diagnostic testing services was strong across its physician, hospital and consumer channels, Quest said.
The results were "well above what was widely expected," Barclays analysts said. 
Industry peer Labcorp LH.N also raised its annual revenue and profit forecasts last quarter, after posting quarterly results above expectations as demand for diagnostic testing remained steady.
Quest Diagnostics reported second-quarter revenue of $3.04 billion, topping analysts' average estimate of $2.97 billion, according to data compiled by LSEG.
Adjusted profit was $3.12 per share, above expectations of $2.83 per share.

        Revenue from diagnostic information services, Quest's largest segment, increased 10.3% to $2.98 billion from a year ago, helped by a 13.1% increase in requisition volumes, including 13.0% organic volume growth.
Quest also reported double-digit growth in advanced diagnostics businesses, including Alzheimer's disease blood tests, advanced cardiometabolic tests and liver fibrosis testing.
The company expects 2026 revenue of $11.95 billion to $12.05 billion, above its prior forecast of $11.78 billion to $11.90 billion and analysts' estimate of $11.85 billion.
Quest expects adjusted profit of $11.05 to $11.25 per share in 2026, compared with its previous forecast of $10.63 to $10.83 per share. Analysts expect $10.76 per share.

 (Reporting by Sahil Pandey in Bengaluru; Editing by Shreya Biswas)
 ((Sahil.Pandey@thomsonreuters.com;))